Outputs (7)

Feasibility of whole-body MRI for cancer screening in children and young people with ataxia telangiectasia: A mixed methods cross-sectional study (2024)
Journal Article
Neves, R., Panek, R., Clarkson, K., Wilne, S., Panagioti, O., Suri, M., Whitehouse, W. P., Fernandez, N. S., Dandapani, M., Glazebrook, C., Dineen, R. A., & Jagani, S. (2024). Feasibility of whole-body MRI for cancer screening in children and young people with ataxia telangiectasia: A mixed methods cross-sectional study. Cancer Medicine, 13(14), Article e70049. https://doi.org/10.1002/cam4.70049

Background/Objectives: Ataxia telangiectasia (A‐T) is an inherited multisystem disorder with increased sensitivity to ionising radiation and elevated cancer risk. Although other cancer predisposition syndromes have established cancer screening protoc... Read More about Feasibility of whole-body MRI for cancer screening in children and young people with ataxia telangiectasia: A mixed methods cross-sectional study.

Characterisation of Expression the Arginine Pathway Enzymes in Childhood Brain Tumours to Determine Susceptibility to Therapeutic Arginine Depletion (2022)
Journal Article
Bishop, E., Dimitrova, M., Froggatt, A., Estevez-Cebrero, M., Storer, L. C. D., Mussai, F., Paine, S., Grundy, R. G., & Dandapani, M. (2022). Characterisation of Expression the Arginine Pathway Enzymes in Childhood Brain Tumours to Determine Susceptibility to Therapeutic Arginine Depletion. BioMed Research International, 2022, Article 9008685. https://doi.org/10.1155/2022/9008685

Despite significant improvements in treatment and survival in paediatric cancers, outcomes for children with brain tumours remain poor. Novel therapeutic approaches are needed to improve survival and quality of survival. Extracellular arginine depend... Read More about Characterisation of Expression the Arginine Pathway Enzymes in Childhood Brain Tumours to Determine Susceptibility to Therapeutic Arginine Depletion.

EPCT-03. Working together to accelerate the preclinical to clinical translation of drug delivery systems for children’s brain tumours (2022)
Presentation / Conference Contribution
Campbell, E., Aquilina, K., Dandapani, M., Walker, D., & Rahman, R. EPCT-03. Working together to accelerate the preclinical to clinical translation of drug delivery systems for children’s brain tumours

Children's brain tumours are the biggest cancer killer in children and young adults. Several techniques, such as intra-cerebrospinal fluid chemotherapy, ultrasound-mediated blood-brain barrier disruption, convection enhanced delivery, polymer deliver... Read More about EPCT-03. Working together to accelerate the preclinical to clinical translation of drug delivery systems for children’s brain tumours.

EPEN-21. Developing a sensitive method for detection of minimal residual disease in ependymoma using metabolomic analysis of cerebrospinal fluid (2022)
Presentation / Conference Contribution
Woodward, A., Amugi, L., Patel, K., Kilpatrick, C., Kim, D.-H., & Dandapani, M. EPEN-21. Developing a sensitive method for detection of minimal residual disease in ependymoma using metabolomic analysis of cerebrospinal fluid

Ependymoma (EPN) is the second most common malignant paediatric brain tumour with poor survival and significant neuro-cognitive impairment from current treatments (surgery and radiotherapy). Relapse occurs in 50% of patients within 2 years, despite n... Read More about EPEN-21. Developing a sensitive method for detection of minimal residual disease in ependymoma using metabolomic analysis of cerebrospinal fluid.

Multicentre service evaluation of presentation of newly diagnosed cancers and type 1 diabetes in children in the UK during the COVID-19 pandemic (2021)
Journal Article
Williams, G., McLean, R., Liu, J. F., Ritzmann, T. A., Dandapani, M., Shanmugavadivel, D., Sachdev, P., Brougham, M., Mitchell, R. T., Conway, N. T., Law, J., Cunnington, A., Ogunnaike, G., Brougham, K., Bayman, E., & Walker, D. (2021). Multicentre service evaluation of presentation of newly diagnosed cancers and type 1 diabetes in children in the UK during the COVID-19 pandemic. BMJ Paediatrics Open, 5(1), Article e001078. https://doi.org/10.1136/bmjpo-2021-001078

Background The COVID-19 pandemic led to changes in patterns of presentation to emergency departments. Child health professionals were concerned that this could contribute to the delayed diagnosis of life-threatening conditions, including childhood ca... Read More about Multicentre service evaluation of presentation of newly diagnosed cancers and type 1 diabetes in children in the UK during the COVID-19 pandemic.

AMP-Activated Protein Kinase: Friend or Foe in Cancer? (2019)
Journal Article
Vara-Ciruelos, D., Dandapani, M., & Hardie, D. G. (2020). AMP-Activated Protein Kinase: Friend or Foe in Cancer?. Annual Review of Cancer Biology, 4(1), 1-16. https://doi.org/10.1146/annurev-cancerbio-030419-033619

The AMP-activated protein kinase (AMPK) is activated by energy stress and restores homeostasis by switching on catabolism, while switching off cell growth and proliferation. Findings that AMPK acts downstream of the tumor suppressor LKB1 have suggest... Read More about AMP-Activated Protein Kinase: Friend or Foe in Cancer?.

Genotoxic Damage Activates the AMPK-α1 Isoform in the Nucleus via Ca2þ/CaMKK2 Signaling to Enhance Tumor Cell Survival (2017)
Journal Article
Vara-Ciruelos, D., Dandapani, M., Gray, A., Egbani, E. O., Evans, A. M., & Hardie, D. G. (2018). Genotoxic Damage Activates the AMPK-α1 Isoform in the Nucleus via Ca2þ/CaMKK2 Signaling to Enhance Tumor Cell Survival. Molecular Cancer Research, 16(2), 345-357. https://doi.org/10.1158/1541-7786.mcr-17-0323

2017 American Association for Cancer Research. Many genotoxic cancer treatments activate AMP-activated protein kinase (AMPK), but the mechanisms of AMPK activation in response to DNA damage, and its downstream consequences, have been unclear. In this... Read More about Genotoxic Damage Activates the AMPK-α1 Isoform in the Nucleus via Ca2þ/CaMKK2 Signaling to Enhance Tumor Cell Survival.